: Lexeo Therapeutics’ stock falls 15% in trading debut after its IPO priced below range

Lexeo Therapeutics Inc.’s stock LXEO tumbled 15% in its trading debut on Friday, after the company’s initial public offering priced below the proposed price range. The stock priced at $11, below a $13 to $15 range. The stock is trading on Nasdaq under the ticker “LXEO.” The company sold 9 million shares to raise $99 million at a valuation of $271.7 million. “We are a clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally...